RCKT
Rocket Pharmaceuticals Inc.
$3.18
+$0.11(+3.58%)
18
Overall
--
Value
18
Tech
--
Quality
Market Cap
$331.26M
Volume
3.04M
52W Range
$2.19 - $20.31
Target Price
$8.60
Order:
Income Statement
| Metric | Trend | Chart | 2015 Dec | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | -- | -- | -- | $100.0K | -- | -- | -- | -- | $10.7M | -- | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | -- | -- | -- | -- | -- | $1.1M | $1.1M | $1.2M | $1.4M | $1.5M | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | -- | -- | -- | $100.0K | -- | $-1.1M | $-1.1M | $-1.2M | $10.7M | $-1.5M | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $20.4M | $-7.6M | $-19.8M | $-71.2M | $76.2M | $134.3M | $167.2M | $223.8M | $259.7M | $273.2M | ||
| Research & Development | $12.6M | $32.0M | $14.9M | $53.3M | $58.6M | $105.4M | $125.5M | $165.6M | $186.3M | $171.2M | ||
| Research Expense | $12.6M | $32.0M | $14.9M | $53.3M | $58.6M | $105.4M | $125.5M | $165.6M | $186.3M | $171.2M | ||
| Selling, General & Administrative | $7.8M | $9.9M | $4.9M | $17.9M | $17.5M | $28.9M | $41.8M | $58.8M | $73.3M | $102.0M | ||
| General & Administrative Expenses | $7.8M | $9.9M | $4.9M | $17.9M | $17.5M | $28.9M | $41.8M | $58.8M | $73.3M | $102.0M | ||
| Salaries & Wages | -- | $-2.9M | $-1.3M | $-13.6M | -- | $-18.6M | $-29.2M | -- | $39.4M | $43.9M | ||
| Depreciation & Amortization | $-45.0K | $-169.0K | $-204.0K | $-801.0K | $-1.2M | $580.0K | $2.9M | $47.0K | $4.9M | $7.2M | ||
| Depreciation & Amortization | $-45.0K | $-169.0K | $-204.0K | $-801.0K | $-1.2M | $580.0K | $2.9M | $47.0K | $-10.7M | $7.2M | ||
| Amortization | $-107.0K | -- | -- | $-801.0K | $-1.2M | $580.0K | $2.9M | $47.0K | $41.3M | $41.3M | ||
| Other Operating Expenses | $-49.0K | $-149.0K | $-19.8M | $-71.2M | $76.2M | $-134.3M | $-645.0K | $4.8M | $259.7M | $273.2M | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-20.4M | $-41.9M | $-19.8M | $-70.4M | $-76.2M | $-134.3M | $-167.2M | $-224.3M | $-259.7M | $-273.2M | ||
| EBITDA | $-62.7M | $-41.0M | $-25.5M | $-65.3M | $-67.6M | $-125.9M | $-157.8M | $-213.7M | $-238.8M | $-249.6M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | $1.2M | $1.4M | $3.6M | $6.0M | $6.0M | $7.5M | $5.9M | $1.9M | $1.9M | $1.9M | ||
| Intinc | $89.0K | $443.0K | $2.0K | $1.7M | $3.4M | $2.1M | $3.1M | $3.9M | $5.3M | $8.3M | ||
| Net Non-Operating Interest Income/Expense | $-1.1M | $-975.0K | $2.0K | $-4.3M | $-2.5M | $-4.8M | $91.0K | $-2.0M | $3.4M | $14.5M | ||
| Gain on Sale of Securities | $-42.8M | $55.0K | $38.0K | $127.0K | $100.0K | -- | $100.0K | $200.0K | $700.0K | -- | ||
| Other Income/Expense | $42.5M | $-55.0K | $-255.0K | $-127.0K | $-100.0K | $26.6M | $-1.0M | $-500.0K | $-700.0K | -- | ||
| Other Special Charges | $267.0K | -- | -- | -- | $31.5M | $-26.6M | $1.0M | $500.0K | -- | -- | ||
| SPECIAL ITEMS | ||||||||||||
| Special Income Charges | -- | -- | -- | -- | $300.0K | -- | -- | -- | -- | -- | ||
| Other Impairment Of Capital Assets | -- | -- | $-217.0K | -- | -- | -- | -- | -- | -- | -- | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-62.8M | $-41.4M | $-25.9M | $-68.7M | $-71.6M | $-132.2M | $-163.2M | $-220.0M | $-243.7M | $-256.9M | ||
| Pre-Tax Income | $-64.1M | $-42.9M | $-19.8M | $-74.7M | $-77.5M | $-139.7M | $-169.1M | $-221.9M | $-245.6M | $-258.7M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | $4.4M | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| NET INCOME | ||||||||||||
| Net Income | $-68.0M | $-42.9M | $-19.6M | $-74.5M | $-77.3M | $-139.7M | $-169.1M | $-221.9M | $-245.6M | $-258.7M | ||
| Net Income (Continuing Operations) | $-68.0M | $-42.9M | $-19.6M | $-74.5M | $-77.3M | $-139.7M | $-169.1M | $-221.9M | $-245.6M | $-258.7M | ||
| Net Income (Discontinued Operations) | $-68.0M | $-42.9M | $-19.6M | $-74.5M | $-77.3M | $-139.7M | $-169.1M | $-221.9M | $-245.6M | $-258.7M | ||
| Net Income (Common Stockholders) | $-68.0M | $-42.9M | $-19.6M | $-74.5M | $-77.3M | $-139.7M | $-169.1M | $-221.9M | $-245.6M | $-258.7M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | -- | -- | -- | $-256.2M | ||
| TOTALS | ||||||||||||
| Total Expenses | $20.4M | $-7.6M | $-19.8M | $-71.2M | $76.2M | $135.4M | $168.3M | $223.8M | $261.1M | $274.7M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $4.6M | $6.7M | $1.7M | $39.4M | $49.0M | $55.4M | $63.2M | $68.1M | $84.0M | $94.8M | ||
| Average Shares Outstanding (Diluted) | $4.6M | $6.7M | $1.7M | $39.4M | -- | $13.0M | $63.2M | $68.1M | $84.0M | $94.8M | ||
| Shares Outstanding | $6.6M | $6.7M | $9.9M | $45.1M | $55.1M | $61.8M | $64.5M | $79.3M | $90.5M | $106.6M | ||
| Basic EPS | -- | -- | -- | -- | $-1.58 | -- | $-2.67 | $-3.26 | $-2.92 | $-2.73 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | -- | $-1.58 | -- | -- | $-3.26 | $-2.92 | $-2.73 | ||
| Diluted EPS | $-14.88 | $-6.4 | $-17.44 | $-1.89 | $-1.58 | $-2.52 | $-2.67 | $-3.26 | $-2.92 | $-2.73 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | -- | -- | -- | -- | $-3.26 | $-2.92 | $-2.73 | ||
| OTHER METRICS | ||||||||||||
| Loss And Loss Adjustment Expected Incurred | -- | -- | -- | -- | -- | $-26.6M | $-12.8M | -- | -- | -- | ||
| Net Income From Other Gains Losses | $480.0K | -- | $192.0K | $186.0K | $250.0K | -- | $1.0M | $500.0K | -- | -- | ||
| Other Gand A | $7.8M | $9.9M | $4.9M | $17.9M | $17.5M | $28.9M | $41.8M | $58.8M | $73.3M | $102.0M | ||
| Otherunder Preferred Stock Dividend | $-131.0K | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Preferred Stock Dividends | $-131.0K | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Rent And Landing Fees | $7.8M | $9.9M | $4.9M | $17.9M | $900.0K | $27.9M | $41.8M | -- | -- | -- | ||
| Othspecchg | -- | -- | -- | -- | $-300.0K | -- | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | RCKT | $3.18 | +3.6% | 3.04M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Rocket Pharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW